Kartini, Diani and Taher, Akmal and Panigoro, Sonar and Setiabudy, Rianto and Jusman, Sri and Haryana, Sofia and Murdani, Abdullah and Rustamadji, Primariadewi and Karisyah, Adlina and Rasyid, Sani (2021) Melatonin effect on hypoxia inducible factor-1a and clinical response in patients with oral squamous cell carcinoma receiving neoadjuvant chemotherapy: A randomized controlled trial. Journal of Carcinogenesis, 20 (1). ISSN 09746773
Full text not available from this repository. (Request a copy)Abstract
Context: Chemoresistance is a major issue in patients with locally advanced oral squamous cell carcinoma (OSCC). In this study, we evaluated the effectiveness of melatonin in conjunction with neoadjuvant chemotherapy (NC) on hypoxia-inducible factor-1α (HIF-1α) expression and clinical response in locally advanced OSCC patients. Aims: To study the effects of melatonin on HIF-1α expression and its effect on the clinical response of patients with locally advanced OSCC. Settings and Design: A randomized controlled trial was conducted, wherein patients were recruited from several hospitals in Jakarta, Indonesia. Patients were randomized into two groups using computerized block randomization. Subjects and Methods: Both groups were given NC, with treatment group receiving melatonin. Outcomes measured in this study were HIF-1α expression from tissue samples and clinical response based on the RECIST 1.1 criteria. Twenty-five patients completed the study protocol and were included in the data analysis. Statistical Analysis Used: Shapiro-Wilk test was used to test the data normality. For data with normal distribution, we conducted an independent t-test to compare between the two groups. Data with abnormal distribution were analyzed using Mann-Whitney U-test. The mean difference between the two groups was analyzed using Shapiro-Wilk normality test. Results: Our study showed a significant decrease in HIF-1α expression in the melatonin group compared to the placebo group (P < 0.05, relative risk 3.08). However, the degree of reduction of HIF-1α expression in the melatonin group did not differ significantly (P = 0.301). Conclusions: Our study showed that melatonin administered at 20 mg/day could reduce the expression of HIF-1α and residual tumor percentage, but did not affect the clinical response in OSCC patients. © 2021 Annual Reviews Inc.. All rights reserved.
Item Type: | Article |
---|---|
Additional Information: | Cited by: 11; All Open Access, Bronze Open Access, Green Open Access |
Uncontrolled Keywords: | carboplatin; cisplatin; docetaxel; fluorouracil; hypoxia inducible factor 1alpha; melatonin; messenger RNA; placebo; adult; advanced cancer; adverse drug reaction; aged; Article; cancer combination chemotherapy; cancer patient; cancer staging; cancer tissue; clinical article; clinical outcome; comparative study; computerized block randomization; controlled study; data analysis software; double blind procedure; drowsiness; fatigue; female; headache; human; human tissue; incisional biopsy; Indonesia; Karnofsky Performance Status; male; microcapsule; mouth squamous cell carcinoma; neoadjuvant chemotherapy; parallel design; protein expression; randomization; randomized controlled trial; real time polymerase chain reaction; response evaluation criteria in solid tumors; risk factor; sleep disorder; treatment response; tumor localization |
Subjects: | R Medicine > RB Pathology |
Divisions: | Faculty of Medicine, Public Health and Nursing > Public Health and Nutrition |
Depositing User: | Sri JUNANDI |
Date Deposited: | 17 Sep 2024 03:42 |
Last Modified: | 17 Sep 2024 03:42 |
URI: | https://ir.lib.ugm.ac.id/id/eprint/4874 |